A. Ernest Toth Jr. - 07 Mar 2024 Form 4 Insider Report for Aquestive Therapeutics, Inc. (AQST)

Role
SVP, Chief Financial Officer
Signature
/s/ Lori J. Braender, as Attorney-In-Fact
Issuer symbol
AQST
Transactions as of
07 Mar 2024
Net transactions value
$0
Form type
4
Filing time
11 Mar 2024, 10:36:17 UTC
Previous filing
09 Aug 2023
Next filing
12 Mar 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AQST Common Stock Award $0 +120,000 +86% $0.000000 260,000 07 Mar 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AQST Non-Qualified Stock Option (right to buy) Award $0 +60,000 $0.000000 60,000 07 Mar 2024 Common Stock 60,000 $5.68 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Common Stock is represented by restricted stock which will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.
F2 The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.